Reduction of harmful reactive oxygen species in reperfusion injury

The phrase "Reperfusion injury prevention via reduction of harmful reactive oxygen species" does not refer to a specific molecule or receptor but rather describes a therapeutic strategy aimed at mitigating tissue damage that occurs when blood supply returns to previously ischemic tissues. This damage is primarily caused by the overproduction of reactive oxygen species (ROS) from sources including mitochondria, NADPH oxidases, xanthine oxidase, and uncoupled nitric oxide synthase during the early phase after reperfusion. Excessive ROS leads to oxidative stress that damages cellular components—lipids, proteins, DNA—and triggers inflammation and cell death pathways. Multiple drug classes are under investigation or clinical use targeting these processes by either inhibiting key enzymatic sources of ROS production or enhancing endogenous antioxidant defenses. However, because this entry is not a discrete molecular target but an entire pathophysiological process involving many molecules and pathways across different cell types—including cardiomyocytes, endothelial cells, inflammatory cells like neutrophils/macrophages/platelets—it should not be considered a canonical therapeutic target itself but rather an area encompassing several validated targets for intervention. If you need structured information on specific molecular targets within this pathway—such as "NADPH oxidase 2", "xanthine oxidase", "mitochondrial permeability transition pore", etc.—please specify which one so detailed data can be provided.

Other names

Reactive oxygen species (ROS) reduction in ischemia-reperfusion injuryROS scavenging in reperfusionAntioxidant therapy for reperfusion injury

Inhibition of ROS-producing enzymes such as NADPH oxidase and xanthine oxidase; Enhancement of endogenous antioxidant systems via NRF2 activation